https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-transition-of-chief-financial-officer/ 2026-08-19T14:50:49+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference/ 2026-09-08T07:30:00+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-fda-clearance-to-initiate-clinical-study-of-ns002-in-the-treatment-of-anaphylaxis/ 2026-09-14T08:00:00+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-reports-first-half-2026-financial-results-and-provides-business-update/ 2026-09-22T12:21:31+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-appoints-pharmaceutical-industry-veteran-brendan-p-ogrady-as-chief-executive-officer-to-lead-strategic-growth/ 2026-09-22T12:23:28+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-to-host-virtual-kol-event-on-june-10-2026-to-discuss-ns002-for-the-treatment-of-anaphylaxis/ 2026-09-22T12:27:32+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-positive-top-line-data-from-phase-2-clinical-study-of-ns002-achieves-significantly-superior-and-faster-epinephrine-delivery-compared-to-epipen-with-accelerated-speed-to-t/ 2026-09-22T12:28:04+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-advances-ns002-towards-pivotal-study-following-positive-phase-2-reports-annual-results-and-provides-business-update/ 2026-09-22T12:29:30+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-to-participate-in-the-zacks-life-sciences-investor-forum/ 2026-09-22T12:30:01+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-positive-results-from-preclinical-pharmacokinetic-and-safety-study-of-intranasal-ondansetron-ns003/ 2026-09-22T12:33:44+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-to-participate-in-upcoming-investor-conferences-2/ 2026-09-22T12:37:34+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-to-present-positive-clinical-results-from-recent-studies-of-fmxin002-ns002-intranasal-epinephrine-at-the-2025-aaaai-annual-meeting/ 2026-09-22T12:42:54+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-marks-nyse-american-listing-with-bell-ringing-ceremony/ 2026-09-22T12:44:53+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-expanded-agreement-to-support-development-and-commercialization-of-ns002-intranasal-epinephrine-program/ 2026-09-22T12:45:23+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-upcoming-presentation-at-h-c-wainwright-27th-annual-global-investment-conference/ 2026-09-22T12:47:53+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-approval-from-health-canada-to-initiate-planned-phase-2-clinical-study-of-ns002-intranasal-epinephrine-powder/ 2026-09-22T12:48:51+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-pricing-of-15-0-million-private-placement/ 2026-09-22T12:49:16+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-positive-clinical-results-of-recent-phase-2-study-with-fmxin002-intranasal-epinephrine/ 2026-09-22T12:49:48+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-strengthens-leadership-team-appointing-eyal-rubin-as-executive-vice-president-and-chief-financial-officer/ 2026-09-22T12:51:30+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-pricing-of-10-million-initial-public-offering/ 2026-09-22T12:52:22+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-positive-results-from-a-pilot-clinical-study-of-fmxin002-intranasal-powder-epinephrine-spray-in/ 2026-09-22T12:52:49+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-positive-results-in-naloxone-pivotal-trial/ 2026-09-22T12:54:41+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-closing-of-15-0-million-private-placement/ 2026-09-22T12:58:03+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-to-present-topline-analysis-from-ns002-intranasal-epinephrine-powder-phase-2-single-and-repeat-dose-clinical-study/ 2026-09-22T12:58:57+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-to-present-and-participate-in-the-upcoming-life-sciences-investor-forum/ 2026-09-22T12:59:26+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-to-participate-in-upcoming-investor-conferences/ 2026-09-22T13:00:17+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-positive-clinical-results-of-recent-phase-2-study-with-fmxin002-intranasal-epinephrine-copy/ 2026-09-22T13:00:47+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026/ 2026-09-22T13:01:17+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-ceo-issues-2025-letter-to-shareholders/ 2026-09-22T13:01:39+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-positive-interim-results-from-phase-2-clinical-study-of-ns002-intranasal-epinephrine-powder/ 2026-09-22T13:02:06+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-closing-of-initial-public-offering/ 2026-09-22T13:03:14+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-initiation-of-phase-2-clinical-study-of-ns002-with-first-participant-dosed/ 2026-09-22T13:03:42+00:00 https://ir.nasuspharma.com/press_releases/nasus-pharma-announces-enrollment-and-dosing-of-first-patient-in-phase-1-study-of-ns003-intranasal-formulation-of-ondansetron/ 2026-09-29T08:00:00+00:00